The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Updates on the QUINTESSENTIAL trial: second-generation anti-GPRC5D CAR-T in myeloma
Susan Bal, MD, University of Alabama at Birmingham, Birmingham, AL, briefly discusses the QUINTESSENTIAL trial (NCT06297226), which evaluates BMS-986393, a second-generation autologous anti-GPRC5D CAR T-cell therapy, in patients with multiple myeloma (MM). Phase I results showed an encouraging response rate of 91% at the recommended Phase II dose, with fewer off-target toxicities compared to other GPRC5D therapies, and the study is now progressing to a larger Phase II trial. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
